Cure My Disease

Don't miss your cure!

 Log in / Sign up

Big data takes on heart disease: can a toolbox of info boost statin use?

NCT ID NCT04067297

Knowledge-focused Sponsor: Institute for Clinical Evaluative Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 'toolbox' of educational materials—including report cards for doctors, patient handouts, and an online decision aid—can increase the use of cholesterol-lowering statins in communities with high rates of heart disease. Researchers will track prescription data from over 500,000 people in Ontario using big data. The goal is to see if this real-world approach helps prevent heart attacks and strokes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lipid management toolbox (educational materials, report cards, decision aid, videos)
What this could lead to
If successful, this approach could show that using big data in real-world settings can improve cholesterol management and prevent heart attacks and strokes in high-risk communities.
What could go wrong
This is an observational-style trial testing a community-level intervention, not a new drug. The results may not apply to other regions or populations, and the toolbox may not change prescribing habits as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2019

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Community with CVD incidence rates higher than the Ontario provincial average * Community with a population size greater than 5,000 40 to 75 year olds * Community with at least 1,000 66 to 75 year olds * Community with 20 to 130 active and practicing family physicians Exclusion Criteria: * Patients with established CVD within each community

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder cardiovascular disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases Cardiovascular risk factor Dyslipidemias

Contacts and locations

Locations

  • ICES

    Toronto, Ontario, M4N3M5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.